• One-Stop CAR-T Therapy Development
  • Biomarker Identification & Selection
  • scFv Generation
  • CAR Design & Construction
  • CAR-T Gene Packaging & Delivery
  • Replication-Competent Virus Testing Service
  • CAR Cell In Vitro Assay Service
  • CAR-T Preclinical In Vivo Assay
  • IND Development for CAR-T Cell Therapy
  • GMP Production for CAR-T Products
  • CAR Clinical Trials
• One-Stop TCR-T Therapy Development
  • TCR Biomarker Identification & Selection
  • TCR Generation & Optimization
  • TCR Design & Construction
  • TCR Gene Packaging & Delivery
  • TCR In Vitro Assay
  • TCR-T Preclinical In Vivo Assay
  • TCR Analysis
  • TCR Clinical Applications
• One-Stop CAR-MA Therapy Development
• One-Stop CAR-NK Therapy Development
  • One-stop CAR-NKT Therapy Development
  • One-stop UniCAR-NK Therapy Development
  • iPSC-derived CAR-NK Therapy Development
  • One-stop TCR-NK Therapy Development
  • NK Cell Genetic Engineering Service
  • NK Cell Expansion Service
• One-stop Cytokine Release Syndrome (CRS) Management Solutions
• One-Stop CAR-B Therapy Development
• TCR-Like Antibody Development Service
  • MHC/Peptide Complex Production for TCR-Like Antibody Discovery
  • TCR-Like Antibody Discovery Strategies
  • TCR-Like Antibody Affinity Characterization
  • TCR-Like CAR Construction and Evaluation Service
• γδ T Cells Engineering Services
• One-Stop Canine CAR-T Therapy Development Services
  • Canine CAR-T Engineering Service
  • Canine CAR-T Development Service for Hematologic Malignancies
  • Canine CAR-T Development Service for Solid Tumor
  • Canine CAR-T Cell Characterization Service
• CellRapeutics™ In Vivo Cell Engineering Development Services
  • In Vivo CAR-T Cell Engineering
  • In Vivo B Cell Engineering
  • In Vivo CAR-NK Cell Engineering
  • In Vivo CAR-M Cell Engineering
• scFv-TCR T Cell Therapy Development Service
• One-Stop Silence™ CAR-T Cell Therapy Development Services
• One-Stop mRNA CAR-T Therapy Development
• Vaccine Boosting CAR-T Cell Therapy Solutions Against Solid Tumors
  • Peptide-DC Vaccine Boosting pMHC-directed CAR-T Cell Solutions
  • Amphiphile-ligand Vaccine Boosting CAR-T Cell Solutions
  • RNA Vaccine Boosting CAR-T Cell Solutions
  • Virus-based Vaccine Boosting CAR-T Cell Solutions
• CellRapeutics™ STAb-T Cell Therapy Development
• CellRapeutics™ CART Therapy Development Services in the Non-Cancer Field
  • CellRapeutics™ CART Development Service for Autoimmune Diseases
  • CellRapeutics™ CART Development Service Powering Anti-Aging Field
  • CellRapeutics™ CART Development Service for Fibrotic Diseases
  • CellRapeutics™ CART Development Service Targeting Infectious Diseases
• One-Stop Allogeneic Cell Therapy Development Services
  • Allogeneic CAR-T Therapy Development Services
  • Allogeneic TCR-T Therapy Development Services
  • Allogeneic CAR-NK Therapy Development Services
  • Allogeneic CAR/TCR Cell Design and Engineering Services
  • Other Allogeneic Cell Therapy Development Services
• CellRapeutics™ Anti-HIV CAR Cell Therapy Development
  • HIV CAR Design and Construction
  • HIV CAR Cell Design and Engineering
• CellRapeutics™ Antibody-TCR (AbTCR) Technology
• Organoid-induced Differentiation of Conventional T Cells from hPSCs
• Modular CAR-T Cell Generation with AAV-Cpf1
• High-throughput Screening for T Cell Activity Modulator Discovery
• Nanoparticle Tiny Tech for Programming T Cells
• TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology
  • NR4A Knock Out CAR-T Cell Development with CRISPR Technology
• Virus Specific T Cell (VST) Technology
• Antibody-Coupled T Cell Receptor (ACTR) Platform
• CellRapeutics™ TCR/CAR/Antigen-Engineered Regulatory T Cells (Tregs)
  • CellRapeutics™ CAR-Treg Development
• CellRapeutics™ Chimeric Engulfment Receptor (CER) Technology
• Dendritic Vaccine Development
  • Induction of Antitumor Cytotoxic Lymphocytes Using Engineered Human Primary Blood Dendritic Cells
• Bispecific TCR Development
• Cancer Vaccine Development
  • Cancer Vaccine Discovery
  • Cancer Vaccine Engineering
  • Cancer Vaccine Analytical Characterization
  • Cancer Vaccine In Vivo Assessment
  • Cancer Vaccine GMP Manufacturing
• One-Stop CAR-Monocyte Therapy Development
• Other Services
  • HLA Typing Service
  • KIR Typing Service
  • HLA Testing
  • Tumor-infiltrating Lymphocytes-based Antibody Discovery Service
  • Dog DLA Genotyping Service
  • Guinea Pig GPLA Genotyping Service
  • Mouse H2 Genotyping Service
  • Rabbit RLA Genotyping Service
  • Rat RT1 Genotyping Service
  • Rhesus Macaque MHC Genotyping Service

CellRapeutics™ CART Development Service Powering Anti-Aging Field

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Cellular Senescence & Aging

Aging is a multifaceted process involving various biological mechanisms, including genomic instability, telomere attrition, and oxidative stress, which can all lead to the senescence of cells. Senescent cells accumulate in many tissues with advancing age and can drive many of the conditions associated with old age, including diabetes, heart disease, and arthritis. These senescent cells not only lose their ability to perform their original function, but they also produce inflammatory molecules, known as the senescence-associated secretory phenotype (SASP), that can disrupt the function of neighboring cells and stimulate their progression into senescence, leading to various age-related disorders. Given the potential harm of senescent cells, a lot of research has gone into developing therapies that can selectively eliminate them - a concept known as senolytics. At Creative Biolabs, we are dedicated to developing CAR-T cells that specifically target these senescent cells. By identifying unique markers on senescent cells, we design CAR to guide T-cells to recognize and eliminate these cells.

Fig.1 Immune system-mediated interventions to clear senescent cells.¹

Senolytic CAR-T Services at Creative Biolabs

Some studies are exploring CAR-T cell therapy to target and eliminate senescent cells that contribute to aging and age-related diseases. By targeting senescent cells, the anti-aging CAR-T therapies could delay the onset of age-related diseases, slow down the aging process, and possibly even reverse some signs of aging. As a leading service provider, we offer custom development of anti-aging CAR-T cells targeting senescent cells. Our team of highly skilled professionals is dedicated to providing a full range of CAR-T development services, including target validation, CAR design and synthesis, viral packaging, CAR-T cell generation, optimization, and validation. We collaborate closely with our clients throughout the development process to meet their needs and objectives. Whether you are at the early stage of your CAR-T therapy development or require assistance with further optimization, we're here to provide you with the tools, guidance, and professional expertise to ensure the success of your research.

Prospective Targets

At Creative Biolabs, our anti-aging CAR-T development service focuses on developing specific CAR-T cells for senescent cells. We provide end-to-end solutions, from the identification and validation of target molecules such as senescence markers to the preclinical development of CAR-T cells. With our experienced team and cutting-edge facility, we generate CAR-T cells designed to recognize specific markers of senescent cells. For example, some potent targets expressed on senescent cells are NKG2DL, MICA, MICB, and urokinase-type plasminogen activator receptor (uPAR).

We provide the following senolytic CAR T cell development services:

Contact us today to learn more about our anti-aging CAR-T development services.

Reference

1. Khalil, et al.; "Emerging Therapeutic Approaches to Target the Dark Side of Senescent Cells: New Hopes to Treat Aging as a Disease and to Delay Age-Related Pathologies." Cells 12.6 (2023): 915.